Next Article in Journal
Computational Insights on the Mechanism of the Chemiluminescence Reaction of New Group of Chemiluminogens—10-Methyl-9-thiophenoxycarbonylacridinium Cations
Next Article in Special Issue
Cannabis, the Endocannabinoid System and Immunity—the Journey from the Bedside to the Bench and Back
Previous Article in Journal
A New Selective PPARγ Modulator Inhibits Triglycerides Accumulation during Murine Adipocytes’ and Human Adipose-Derived Mesenchymal Stem Cells Differentiation
Previous Article in Special Issue
Immunoregulatory Property of C-Type Lectin-Like Receptors in Fibrosing Interstitial Lung Diseases

OMV Vaccines and the Role of TLR Agonists in Immune Response

GSK Vaccines Institute for Global Health s.r.l (GVGH), 53100 Siena, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(12), 4416;
Received: 4 June 2020 / Revised: 17 June 2020 / Accepted: 18 June 2020 / Published: 21 June 2020
(This article belongs to the Special Issue Immunoregulatory Receptor Signaling Networks)
Outer Membrane Vesicles (OMVs) are bacterial nanoparticles that are spontaneously released during growth both in vitro and in vivo by Gram-negative bacteria. They are spherical, bilayered membrane nanostructures that contain many components found within the external surface of the parent bacterium. Naturally, OMVs serve the bacteria as a mechanism to deliver DNA, RNA, proteins, and toxins, as well as to promote biofilm formation and remodel the outer membrane during growth. On the other hand, as OMVs possess the optimal size to be uptaken by immune cells, and present a range of surface-exposed antigens in native conformation and Toll-like receptor (TLR) activating components, they represent an attractive and powerful vaccine platform able to induce both humoral and cell-mediated immune responses. This work reviews the TLR-agonists expressed on OMVs and their capability to trigger individual TLRs expressed on different cell types of the immune system, and then focuses on their impact on the immune responses elicited by OMVs compared to traditional vaccines. View Full-Text
Keywords: outer membrane vesicle (OMV); GMMA; PAMP; TLR; vaccine outer membrane vesicle (OMV); GMMA; PAMP; TLR; vaccine
Show Figures

Figure 1

MDPI and ACS Style

Mancini, F.; Rossi, O.; Necchi, F.; Micoli, F. OMV Vaccines and the Role of TLR Agonists in Immune Response. Int. J. Mol. Sci. 2020, 21, 4416.

AMA Style

Mancini F, Rossi O, Necchi F, Micoli F. OMV Vaccines and the Role of TLR Agonists in Immune Response. International Journal of Molecular Sciences. 2020; 21(12):4416.

Chicago/Turabian Style

Mancini, Francesca, Omar Rossi, Francesca Necchi, and Francesca Micoli. 2020. "OMV Vaccines and the Role of TLR Agonists in Immune Response" International Journal of Molecular Sciences 21, no. 12: 4416.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop